FDA APPROVED DRUGS

FDA Approves New Drug For Schizophrenia Therapy On 26 September 2024, the U.S. Food and Drug Administration granted approval for Cobenfy (xanomeline-trospium), a…

Vorasidenib: Pioneering Therapy for Grade 2 Gliomas with IDH Mutations Voranigo is a targeted cancer therapy that inhibits mutated isocitrate dehydrogenase enzymes—specifically IDH1…

First Time FDA Approves Nasal Epinephrine Spray for Anaphylaxis Treatment In a groundbreaking development, ARS Pharmaceuticals has received FDA approval for Neffy, the…